Novo Nordisk, the Denmark-based manufacturer of Ozempic, said Sept. 10 it plans to reduce approximately 9,000 of its 78,400 global roles.
The drugmaker said in a news release the workforce reductions will save 8 billion Danish Krone, or about $1 billion, by the end of 2026. Around 5,000 of the layoffs will occur in Denmark.
Novo Nordisk said the move aims to “simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
